Structure Therapeutics Announces Poster Presentations of its Oral GLP-1 Receptor Agonist GSBR-1290 at the American Diabetes Association 83rd Scientific Sessions
June 07 2023 - 8:30AM
Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global
biopharmaceutical company developing novel oral small molecule
therapeutics for metabolic and pulmonary diseases, today announced
that clinical and preclinical data from its oral GLP-1 receptor
agonist GSBR-1290 program will be presented at the upcoming
American Diabetes Association (ADA) 83rd Scientific Sessions taking
place June 23-26, 2023, in San Diego, CA.
“The internal discovery of GSBR-1290 speaks to our expertise and
long-term commitment to leveraging our structure-based drug
discovery platform to design innovative small molecule therapies
against the incretin and gut hormone family of G-protein coupled
receptors,” said Xichen Lin, Ph.D., Chief Scientific Officer of
Structure Therapeutics. “Advancing GSBR-1290 into a first-in-human
Phase 1 study marked a significant milestone for Structure
Therapeutics. This molecule demonstrated encouraging safety and
tolerability and we are looking forward to further studying its
efficacy and safety profile in type 2 diabetes and obesity patients
in the recently initiated Phase 2a study.”
Clinical and pre-clinical presentations include:
Poster presentation (#754): A First-in-Human Single
Ascending Dose Study of GSBR-1290, a Novel Small Molecule GLP-1
Receptor Agonist, in Healthy Volunteers
- Date: Sunday, June 25, 2023
- Presentation Time: 11:30 a.m. – 12:30 p.m.
PT
- Session: Clinical Therapeutics—Incretin-Based
Therapies
Poster presentation (#760): Discovery of GSBR-1290, a
highly potent, orally available, novel small molecule GLP-1
receptor agonist
- Date: Sunday, June 25, 2023
- Presentation Time: 11:30 a.m. – 12:30 p.m.
PT
- Session: Clinical Therapeutics—Incretin-Based
Therapies
A copy of the presentation materials can be accessed by visiting
the “Pipeline” section of the Structure Therapeutics website after
the conclusion of the presentations and will be archived on the
Structure Therapeutics website.
About GSBR-1290GSBR-1290 is an
orally-available, small molecule agonist of the GLP-1 receptor, a
validated drug target for the treatment of type 2 diabetes (T2DM)
and obesity. The Company completed its Phase 1 single ascending
dose (SAD) study in September 2022. GSBR-1290 was generally well
tolerated and demonstrated dose-dependent pharmacokinetic (PK) and
pharmacodynamic (PD) activity in 48 healthy volunteers. The Company
has completed dosing of its Phase 1b multiple ascending dose (MAD)
study focused on safety, PK and tolerability in 24 healthy
volunteers, and has initiated a Phase 2a study in T2DM and obesity.
Topline data from the Phase 1b MAD study and the Phase 2a study are
expected to be announced in the latter half of the fourth quarter
of 2023.
About Structure TherapeuticsStructure
Therapeutics is a leading clinical-stage biopharmaceutical company
focused on discovering and developing innovative oral treatments
for chronic metabolic and pulmonary conditions with significant
unmet medical needs. Utilizing its next generation structure-based
drug discovery platform, the company has established a
scientifically-driven, GPCR-targeted pipeline, featuring two
wholly-owned proprietary clinical-stage small molecule compounds
designed to surpass the limitations of traditional biologic and
peptide therapies and be accessible to more patients around the
world. For additional information, please visit
www.structuretx.com.
Forward Looking StatementsThis press release
contains “forward-looking statements” within the meaning of the
“safe harbor” provisions of the Private Securities Litigation
Reform Act of 1995. All statements other than statements of
historical fact are statements that could be deemed forward-looking
statements, including, without limitation, statements concerning
the Company’s future plans and prospects, any expectations
regarding the safety or efficacy of GSBR-1290 and other candidates
under development, the ability of GSBR-1290 to treat type 2
diabetes, obesity or related indications, plans with respect to
regulatory submissions, the planned timing of the Company’s
clinical trials, data results and continued development of
GSBR-1290 and expectations regarding an oral development candidate
targeting GLP-1R. In addition, when or if used in this press
release, the words “may,” “could,” “should,” “anticipate,”
“believe,” “estimate,” “expect,” “intend,” “plan,” “predict” and
similar expressions and their variants, as they relate to the
Company may identify forward-looking statements. Forward-looking
statements are neither historical facts nor assurances of future
performance. Although the Company believes the expectations
reflected in such forward-looking statements are reasonable, the
Company can give no assurance that such expectations will prove to
be correct. Readers are cautioned that actual results, levels of
activity, safety, performance or events and circumstances could
differ materially from those expressed or implied in the Company’s
forward-looking statements due to a variety of risks and
uncertainties, which include, without limitation, risks and
uncertainties related to the Company’s ability to advance
GSBR-1290, LTSE-2578, ANPA-0073 and its other therapeutic
candidates, obtain regulatory approval of and ultimately
commercialize the Company’s therapeutic candidates, the timing and
results of preclinical and clinical trials, the Company’s ability
to fund development activities and achieve development goals, the
continuing impact of the COVID-19 pandemic, inflation, supply chain
issues, rising interest rates and future bank failures on the
Company’s business, its ability to protect its intellectual
property and other risks and uncertainties described in the
Company’s filings with the Securities and Exchange Commission
(“SEC”), including the Company’s quarterly Report on Form 10-Q
filed with the SEC on May 11, 2023 and future reports the Company
may file with the SEC from time to time. All forward-looking
statements contained in this press release speak only as of the
date on which they were made and are based on management’s
assumptions and estimates as of such date. The Company undertakes
no obligation to update such statements to reflect events that
occur or circumstances that exist after the date on which they were
made, except as required by law.
Contacts:
Investors:Jun Yoon, Chief Financial
OfficerStructure Therapeutics Inc.ir@structuretx.com
Media:Dan Budwick1ABDan@1abmedia.com
Structure Therapeutics (NASDAQ:GPCR)
Historical Stock Chart
From May 2024 to Jun 2024
Structure Therapeutics (NASDAQ:GPCR)
Historical Stock Chart
From Jun 2023 to Jun 2024